Orchid Pharma Ltd

- There is no specific mention of any current or planned new fundraising through debt or equity in the transcript. - A clarification was made that the debt has not increased by INR 1,000 crores, indicating no major new borrowings recently. - The company is focused on operational discipline and maintaining cost stability amid a challenging market. - No discussions or guidance about raising funds via equity or debt were shared during the call. - The management's emphasis is on internal cash flows, licensing deals, and improving business fundamentals rather than new external financing at this stage.

- The 7ACA project is progressing as per revised timelines with all fermenters erected and major equipment installation ongoing. This project aims to strengthen Orchid's API manufacturing base and reduce import dependency. - The Cefiderocol project building structure is nearly complete, with equipment deliveries started, targeting production readiness by Q4 of FY26. - Operational discipline focuses on maintaining cost stability amid inflation and market pressures. - The company is investing in expanding its AMS (Antimicrobial Stewardship) division as a strategic platform, especially for launching Cefiderocol in India. - Orchid plans to out-license Enmetazobactam (Exblifep) globally, aiming for licensing deals in multiple markets within FY26. - While no specific capex figures are disclosed, these projects and initiatives indicate ongoing significant capital investments through FY26 to build long-term growth foundations.

- Financial year 2026 expected to remain muted operationally with no signs of market recovery in the current year. - Focus on building a stronger foundation for recovery and sustainable long-term growth. - Global antibiotics market continues to face prolonged slowdown; no immediate revival signs. - New licensing deals anticipated for Exblifep in multiple geographies to drive future revenues. - Expansion of AMS division to build hospital sales volume, aiming for breakeven by Q4 FY26. - Enmetazobactam and Cefiderocol projects progressing; Cefiderocol production expected by Q4 FY26. - Growth driven through partnerships and licensing in regulated and unregulated markets globally, including India, Europe, U.S., Latin America, and Southeast Asia. - Domestic brand Orblicef showing positive traction with stable and growing segment in Indian hospital antibiotics. - Overall volume growth expected in Asia and Africa due to increased healthcare access; regulated mature markets likely to remain stable.

- FY26 is expected to be muted operationally as the company focuses on building a stronger foundation for recovery and sustainable growth (Page 14). - Licenses for Exblifep (Enmetazobactam) in multiple geographies expected to drive future revenue and profits; new licensing deals anticipated within the next 12 months (Pages 3, 8, 12). - AMS division, currently a drag, is an investment for long-term growth with breakeven expected by Q4 FY26 or by next year (Pages 7-8). - Recovery in gross margins to 40-43% is uncertain in the near term; regulated market demand and pricing remain to be evaluated (Page 11). - Orblicef (domestic brand) showing stable and growing demand in India, contributing positively (Page 3). - Long-term growth expected from operational projects (7ACA, Cefiderocol) and expansion in hospital antibiotic sales (Pages 4, 14). - Revenue/profit visibility for Enmetazobactam expected by end FY26 after licensing deals materialize (Page 12).

The transcript from the Orchid Pharma Limited Q2 FY26 earnings call does not explicitly mention the current or expected order book or pending orders. Key related points are: - The company is focused on signing new licensing deals, especially for Exblifep (Enmetazobactam) in multiple geographies, but concrete progress on new licensing is expected over the coming quarters. - The sales of Orblicef (domestic brand) are progressing well and hospital sales through the AMS division are expanding. - There are ongoing negotiations for partners in the U.S. and other global markets for out-licensing Enmetazobactam. - The Cefiderocol project is targeted for production readiness by Q4 FY26. - No specific figures or quantitative details on order book or pending orders were disclosed during the call.